DeepMatter Group PLC (DMTR.L) Collaboration with the University of Cambridge

DeepMatter collaborates with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies

DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, has commenced a project with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies (iDMT), an open innovation research centre co-funded by the University of Cambridge, AstraZeneca, Shionogi, and the European Regional Development Fund.

DeepMatter will provide its DigitalGlassware® platform to iDMT as part of the development of a fully digital workflow in the discovery and development of new molecules, materials, reactions and processes.

This initiative is part of DeepMatter’s ongoing programme to be closely involved with key opinion leaders in the major universities’ emerging digital chemistry units and follows on from its collaborations with the Universities of Leeds, Glasgow, Sheffield and Nottingham.

The iDMT is a new initiative set up to enable the transformation of chemistry into the fully digital domain including the increased usage of data science, data standardisation, algorithms for discovery and development, automated analytical chemistry, and robotic equipment.

The iDMT supports collaborative research projects with small and medium enterprises (SMEs) from across the UK, aiming to develop a technology base to support the emerging digital economy in the third largest manufacturing sector in the UK.

DigitalGlassware® comprises a cloud-based software platform allowing scientists to easily bring together digitised synthesis protocols (recipes) and contextualised time-course sensor streams from a range of analytical instrumentation, importantly in real-time.

The project will be based in the Yusuf Hamied Department of Chemistry within the University of Cambridge and led by Alexei Lapkin, Professor of Sustainable Reaction Engineering at the University.

Mark Warne, CEO of DeepMatter Group, commented: ” This is another important step in rolling out our flagship platform DigitalGlassware®, with the key opinion leaders in the academic world allowing us to demonstrate publicly its ability to discover new molecules and routes to molecules in a way that would not otherwise be able. The expertise we can garner by engaging with these influential institutions will be invaluable in helping us to innovate our platform even further.

“We are now establishing DigitalGlassware® as the go-to platform for capturing and structuring time-course sensor data in the lab, to enable improved insights for better productivity and discovery.

“The establishment of iDMT is an exciting development for our industry, aiming to spark a digital transformation in the chemical industries. We have a shared focus on data capture and standardisation, data science and robotics and we are looking forward to working within the digital chemistry space at one of the world’s leading universities.”

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

About DeepMatter Group plc

DeepMatter is building and commercialising the most powerful data platforms, to enable scientists to easily perform and optimise chemical reactions, by increasingly integrating chemistry with technology. Ultimately this will allow the greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics.

Visit: and follow @deepmattergroup

About iDMT

The Innovation Centre in Digital Molecular Technologies (iDMT) is an open innovation platform for collaborative R&D projects in the areas of artificial intelligence in molecular technologies, robotic equipment for chemical synthesis, and algorithms and tools for digital process development. The mission of the iDMT is to support UK SMEs in the rapid development and testing of new products and services for the evolving paradigm of the digital economy, specifically in the sectors of chemical synthesis of molecules and materials. The iDMT is co-funded by the University of Cambridge, AstraZeneca, Shionogi and European Regional Development Fund (ERDF).

Visit and follow @iDMTcambridge

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.